AstraZeneca leans into GLP-1; Cuts looming at Bayer; Eli Lilly’s obesity approval; Endpoints Slack interview with Matt Gline; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Both Bayer…
Click here to view original post